Treatment

Real life use of natalizumab and fingolimod in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry

Real life use of natalizumab and fingolimod in Austria: benefit-risk data from the Austrian Multiple Sclerosis Treatment Registry

Dr. Guger discusses the most current research on the use of natalizumab an…

Expiration Date: 2/5/2016

Max Credits: 0

View Activity

Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study

Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study

Dr. Cortese discusses research on the effect of vitamin D levels via cod l…

Expiration Date: 2/5/2016

Max Credits: 0

View Activity

Treatment strategies – determining treatment failure, what to do next

Treatment strategies – determining treatment failure, what to do next

Dr. Miller discusses defining treatment failure discussing subsequent trea…

Expiration Date: 11/12/2016

Max Credits: 0

View Activity

Optimizing Patient Safety and Outcomes by Individualizing Therapy

Optimizing Patient Safety and Outcomes by Individualizing Therapy

Since the approval of interferon beta-1b, multiple additional therapies ha…

Expiration Date: 11/12/2016

Max Credits: 0

View Activity

Making Informed Decisions When Screening and Monitoring

Making Informed Decisions When Screening and Monitoring

Since the approval of interferon beta-1b, multiple additional therapies ha…

Expiration Date: 11/12/2016

Max Credits: 0

View Activity

No evident disease activity in relapsing MS patients treated with interferon β-1a SC vs. interferon β-1a IM: subgroup analyses of the EVIDENCE study

No evident disease activity in relapsing MS patients treated with interferon β-1a SC vs. interferon β-1a IM: subgroup analyses of the EVIDENCE study

Dr. Coyle discusses the most current research on the effect of interferon …

Expiration Date: 11/12/2016

Max Credits: 0

View Activity

Long-term effects of fampridine on walking ability in patients with multiple sclerosis: a phase II, open-label, uncontrolled, monocenter study

Long-term effects of fampridine on walking ability in patients with multiple sclerosis: a phase II, open-label, uncontrolled, monocenter study

Dr. Filli discusses the most current research on the effect of fampridine …

Expiration Date: 11/12/2016

Max Credits: 0

View Activity

MicroRNA miR-21 is induced by interferon-beta and inhibits IL-12 expression: a novel immunomodulatory mechanism in multiple sclerosis

MicroRNA miR-21 is induced by interferon-beta and inhibits IL-12 expression: a novel immunomodulatory mechanism in multiple sclerosis

Dr. Balashov discusses the effect of interferon beta on interleukin-12 in …

Expiration Date: 11/12/2016

Max Credits: 0

View Activity

MS Forum

MS Forum

Multiple sclerosis (MS) is a chronic, immune-mediated inflammatory disease…

Expiration Date: 12/18/2015

Max Credits: 0

View Activity